Clinical trials: Lou Gehrig's Disease

Amyotrophic Lateral Sclerosis

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

• Terminated
• Age: 19 to 75 years
• Phase 1/2

The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.

Trial name

NCT04326283

Testing

Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg)

Where

5 sites in South Korea

Volunteers

23 people

Sponsor

Genuv Inc.